Work

The Role of Oncology Nurses and Advanced Practice Providers in the Treatment of Patients With HRR-Deficient mCRPC Receiving Talazoparib Plus Enzalutamide: A Podcast

Year: 2025

Type: article

Abstract: Homologous recombination repair (HRR) is a DNA repair pathway that helps maintain genomic stability. About one quarter of patients with metastatic castration-resistant prostate cancer (mCRPC) have alterations in HRR genes. For adult patients in the USA with mCRPC harboring HRR gene alterations, the combination of talazoparib plus enzalutamide is an approved treatment option. The objective of this podcast, featuring two nurse practitioners, is to provide information for oncology nurses and advanced practice providers (APPs) on the use of talazoparib plus enzalutamide and its practical implementation aspects in the clinic. We discuss the importance of testing for HRR gene alterations in mCRPC, appropriate dosing and administration, and our clinical experiences of adverse event monitoring and dose modifications as illustrative examples of the role of oncology nurses and APPs in the treatment of mCRPC with talazoparib plus enzalutamide. Podcast and Infographic are available for this article. Podcast Video (MP4 172565 KB).

Source: Oncology and Therapy

DOI: 10.1007/s40487-025-00376-w

Authors: Jennifer L. E. Lloyd, Julia Batten

Institutions: Intermountain Medical Center, Huntsman Cancer Institute

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $7,400